文献速递流行病学与生物统计临床试验与 GCP

住院新生儿与小婴儿脓毒症的抗生素使用模式、病原体及死亡预测:全球新生儿脓毒症观察性队列研究(NeoOBS)

Patterns of antibiotic use, pathogens, and prediction of mortality in hospitalized neonates and young infants with sepsis: A global neonatal sepsis observational cohort study (NeoOBS).
PubMed 文献 · PLoS Med · 2023-06-08

NeoOBS是一项在11个国家19个中心开展的前瞻性观察性队列研究,纳入2018至2020年住院的<60天临床脓毒症婴儿3204例。研究描述了抗生素使用模式、病原体分布及28天死亡率,并开发了基线NeoSep严重度评分预测死亡和NeoSep恢复评分指导方案调整。

要点

  • 初始经验性抗生素方案与WHO指南常不一致,碳青霉烯类使用比例较高。
  • 血培养阳性率17.7%,以革兰阴性菌为主,碳青霉烯耐药常见。
  • 基线NeoSep严重度评分可识别高死亡风险患儿,供临床试验入选参考。

核心结论

  • 新生儿脓毒症所用抗生素方案常偏离WHO指南,在抗菌药物耐药日益严重的背景下,亟需开展新型经验性方案试验。
  • 基线NeoSep严重度评分可识别供试验入选的高死亡风险标准,NeoSep恢复评分有助于指导方案变更决策。

研究设计与样本

  • 前瞻性观察性队列研究,2018至2020年由11个国家(主要为亚洲和非洲)的19个中心纳入<60天住院临床脓毒症婴儿。
  • 共纳入3204例婴儿,中位出生体重2500 g(IQR 1400至3000),中位日龄5天(IQR 1至15)。
  • 前瞻性每日收集临床体征、支持治疗、抗生素治疗、微生物学及28天死亡率数据。
  • 开发两个预测模型:基线NeoSep严重度评分预测28天死亡率,NeoSep恢复评分预测每日静脉抗生素治疗下的死亡风险。
  • 多变量Cox回归模型使用随机选取的85%婴儿,15%用于验证。

主要发现

  • 3141例婴儿启动了206种不同经验性抗生素组合,按WHO AWaRe分类分为5组:25.9%(n=814)起始WHO一线方案(1组-Access),13.8%(n=432)起始WHO二线头孢菌素(头孢噻肟/头孢曲松)(2组-“低”Watch),34.0%(n=1068)起始部分覆盖ESBL/假单胞菌的方案(哌拉西林-他唑巴坦、头孢他啶或氟喹诺酮类)(3组-“中”Watch),18.0%(n=566)起始碳青霉烯类(4组-“高”Watch),1.8%(n=57)起始储备抗生素(5组,主要为多黏菌素类)。
  • 1至4组初始方案中728/2880(25.3%)升级,主要升级至碳青霉烯类,通常因临床恶化(n=480;65.9%)。
  • 564/3195例婴儿(17.7%)血培养病原体阳性,其中62.9%(n=355)为革兰阴性菌,主要为肺炎克雷伯菌(n=132)或不动杆菌属(n=72)。
  • 肺炎克雷伯菌和不动杆菌属对WHO推荐方案常见耐药,对碳青霉烯类耐药分别为43例(32.6%)和50例(71.4%)。
  • 54株金黄色葡萄球菌分离株中MRSA占33株(61.1%)。

临床怎么用

  • 基线NeoSep严重度评分可识别高死亡风险标准用于试验入选,NeoSep恢复评分可帮助指导方案变更决策。
  • NeoOBS数据为NeoSep1抗生素试验(ISRCTN48721236)提供了信息,该试验旨在确定新生儿脓毒症的新型一线和二线经验性抗生素方案。

局限性

  • 各中心结局存在显著差异,外部验证将增强评分的适用性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There is limited data on antibiotic treatment in hospitalized neonates in low- and middle-income countries (LMICs). We aimed to describe patterns of antibiotic use, pathogens, and clinical outcomes, and to develop a severity score predicting mortality in neonatal sepsis to inform future clinical trial design. METHODS AND FINDINGS: Hospitalized infants <60 days with clinical sepsis were enrolled during 2018 to 2020 by 19 sites in 11 countries (mainly Asia and Africa). Prospective daily observational data was collected on clinical signs, supportive care, antibiotic treatment, microbiology, and 28-day mortality. Two prediction models were developed for (1) 28-day mortality from baseline variables (baseline NeoSep Severity Score); and (2) daily risk of death on IV antibiotics from daily updated assessments (NeoSep Recovery Score). Multivariable Cox regression models included a randomly selected 85% of infants, with 15% for validation. A total of 3,204 infants were enrolled, with median birth weight of 2,500 g (IQR 1,400 to 3,000) and postnatal age of 5 days (IQR 1 to 15). 206 different empiric antibiotic combinations were started in 3,141 infants, which were structured into 5 groups based on the World Health Organization (WHO) AWaRe classification. Approximately 25.9% (n = 814) of infants started WHO first line regimens (Group 1-Access) and 13.8% (n = 432) started WHO second-line cephalosporins (cefotaxime/ceftriaxone) (Group 2-"Low" Watch). The largest group (34.0%, n = 1,068) started a regimen providing partial extended-spectrum beta-lactamase (ESBL)/pseudomonal coverage (piperacillin-tazobactam, ceftazidime, or fluoroquinolone-based) (Group 3-"Medium" Watch), 18.0% (n = 566) started a carbapenem (Group 4-"High" Watch), and 1.8% (n = 57) a Reserve antibiotic (Group 5, largely colistin-based), and 728/2,880 (25.3%) of initial regimens in Groups 1 to 4 were escalated, mainly to carbapenems, usually for clinical deterioration (n = 480; 65.9%). A total of 564/3,195 infants (17.7%) were blood culture pathogen positive, of whom 62.9% (n = 355) had a gram-negative organism, predominantly Klebsiella pneumoniae (n = 132) or Acinetobacter spp. (n = 72). Both were commonly resistant to WHO-recommended regimens and to carbapenems in 43 (32.6%) and 50 (71.4%) of cases, respectively. MRSA accounted for 33 (61.1%) of 54 Staphylococcus aureus isolates. Overall, 350/3,204 infants died (11.3%; 95% CI 10.2% to 12.5%), 17.7% if blood cultures were positive for pathogens (95% CI 14.7% to 21.1%, n = 99/564). A baseline NeoSep Severity Score had a C-index of 0.76 (0.69 to 0.82) in the validation sample, with mortality of 1.6% (3/189; 95% CI: 0.5% to 4.6%), 11.0% (27/245; 7.7% to 15.6%), and 27.3% (12/44; 16.3% to 41.8%) in low (score 0 to 4), medium (5 to 8), and high (9 to 16) risk groups, respectively, with similar performance across subgroups. A related NeoSep Recovery Score had an area under the receiver operating curve for predicting death the next day between 0.8 and 0.9 over the first week. There was significant variation in outcomes between sites and external validation would strengthen score applicability. CONCLUSION: Antibiotic regimens used in neonatal sepsis commonly diverge from WHO guidelines, and trials of novel empiric regimens are urgently needed in the context of increasing antimicrobial resistance (AMR). The baseline NeoSep Severity Score identifies high mortality risk criteria for trial entry, while the NeoSep Recovery Score can help guide decisions on regimen change. NeoOBS data informed the NeoSep1 antibiotic trial (ISRCTN48721236), which aims to identify novel first- and second-line empiric antibiotic regimens for neonatal sepsis. TRIAL REGISTRATION: ClinicalTrials.gov, (NCT03721302).

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Russell NJ, Stöhr W, Plakkal N, et al. Patterns of antibiotic use, pathogens, and prediction of mortality in hospitalized neonates and young infants with sepsis: A global neonatal sepsis observational cohort study (NeoOBS). PLoS Med. 2023. PMID: 37289666. doi:10.1371/journal.pmed.1004179

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。